Evaluation of serum levels of C-reactive protein, D-Dimer and Autologous Serum Skin Test in patients with Chronic Spontaneous Urticaria in a Brazilian tertiary center: a cross-sectional study

Abstract Background: The pathophysiology of urticaria is still poorly understood. Recent studies demonstrate that the activation of coagulation is correlated with the clinical activity of Chronic Spontaneous Urticaria. Coagulation and inflammation are strongly linked. Objectives: To correlate the severity and activity of Chronic Spontaneous Urticaria with the levels of D-dimer, C-reactive protein, and autologous serum test in patients with Chronic Spontaneous Urticaria. Methods: The study included 55 patients diagnosed with chronic spontaneous urticaria. D-dimer levels were measured using enzyme-linked fluorescent assay and C-reactive protein levels were measured using the nephelometric method; autologous serum testing was performed on patients who discontinued antihistamine therapy. The severity of the disease was assessed using the urticaria activity score. Results: patients with severe, spontaneous, and difficult-to-control chronic urticaria had elevated serum levels of D-dimer, as well as a positive autologous serum test. Little correlation was demonstrated between the severity of chronic spontaneous urticaria and the levels of C-reactive protein. Conclusion: The authors concluded that patients with severe Chronic Spontaneous Urticaria showed signs of activated fibrinolysis. Most patients with high clinical scores had high D-dimer values. Patients with positive results for the autologous serum test also had more severe Chronic Spontaneous Urticaria and needed more drugs to control the disease. Finally, little correlation was found between C-reactive protein levels and disease severity. Study limitations: The main limitation was the small sample of patients. In the present patients, it was demonstrated that serum D-dimer levels and the autologous serum test can act as predictive markers of severity and activity of Chronic Spontaneous Urticaria.

Evaluation of serum levels of C-reactive protein, D-Dimer and Autologous Serum Skin Test in patients with Chronic Spontaneous Urticaria in a Brazilian tertiary center : a cross-sectional study.

BACKGROUND: The pathophysiology of urticaria is still poorly understood. Recent studies demonstrate that the activation of coagulation is correlated with the clinical activity of Chronic Spontaneous Urticaria. Coagulation and inflammation are strongly linked. OBJECTIVES: To correlate the severity and activity of Chronic Spontaneous Urticaria with the levels of D-dimer, C-reactive protein, and autologous serum test in patients with Chronic Spontaneous Urticaria. METHODS: The study included 55 patients diagnosed with chronic spontaneous urticaria. D-dimer levels were measured using enzyme-linked fluorescent assay and C-reactive protein levels were measured using the nephelometric method; autologous serum testing was performed on patients who discontinued antihistamine therapy. The severity of the disease was assessed using the urticaria activity score. RESULTS: patients with severe, spontaneous, and difficult-to-control chronic urticaria had elevated serum levels of D-dimer, as well as a positive autologous serum test. Little correlation was demonstrated between the severity of chronic spontaneous urticaria and the levels of C-reactive protein. CONCLUSION: The authors concluded that patients with severe Chronic Spontaneous Urticaria showed signs of activated fibrinolysis. Most patients with high clinical scores had high D-dimer values. Patients with positive results for the autologous serum test also had more severe Chronic Spontaneous Urticaria and needed more drugs to control the disease. Finally, little correlation was found between C-reactive protein levels and disease severity. STUDY LIMITATIONS: The main limitation was the small sample of patients. In the present patients, it was demonstrated that serum D-dimer levels and the autologous serum test can act as predictive markers of severity and activity of Chronic Spontaneous Urticaria.

Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes.

Global prevalence of non-alcoholic fatty liver disease (NAFLD) has been growing in the last decades, especially in western countries, due to increased prevalence of diabetes, obesity or other components of metabolic syndrome. NAFLD recently became an important cause of hepatocellular carcinoma (HCC), even in non-cirrhotic patients. Patients with HCC-NAFLD are usually older, with more morbidities (especially cardiovascular diseases and metabolic disorders) and have advanced disease at the diagnosis due to the absence of surveillance, which is considered not cost-effective in patients without advanced fibrosis/cirrhosis, given the large prevalence of NAFLD in the general population. For these reasons, patients with HCC-NAFLD unlikely underwent curative treatments, and have been reported to have lower overall survival (OS) compared to individuals with HCC related to other aetiologies. However, this difference is not confirmed by data of patient subgroups who received curative treatment. In our review, we selected studies published over the past 8 years that analyse characteristics and outcomes of HCC-NAFLD patients who underwent surgery with the aim of identifying features that could predict outcomes and potential selection criteria. All the studies confirm that patients with HCC-NAFLD are older, with many comorbidities and that HCC occurs frequently even in non-cirrhotic livers. There is no agreement about intraoperative and perioperative complications. Regarding outcomes, all papers agree that patients with HCC in NAFLD who undergo surgery have a better OS compared to other aetiologies. Summarizing, surgery is a good curative option for patients with HCC-NAFLD, perhaps even better than transplantation in terms of OS. In this group of patients, it seems to be essential to evaluate cardio-pulmonary and general operative risk, in addition to the normal risk assessment related to liver function to avoid an underestimation, especially for patients without severe underlying fibrosis.

Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral center.

OBJECTIVE: The study aimed to evaluate the long-term efficacy and safety of vedolizumab in a real-life cohort of patients with inflammatory bowel diseases enrolled at a tertiary referral center. METHODS: Data were retrospectively collected from August 2016 to November 2018. The primary outcomes were clinical response and remission at 14, 24, and 52 weeks, and steroid-free remission rate (SFRR) at 52 weeks. Endoscopic response and remission rates at 52 weeks were the secondary outcomes. RESULTS: Altogether 49 patients (22 with ulcerating colitis [UC] and 27 with Crohn's Disease [CD]) were enrolled. The clinical response rate gradually dropped from 85% and 50% in CD and UC, respectively, at week 14 to 59% and 25% at week 52, with significantly a higher response in CD at week 14. The endoscopic response at week 52 was 55% in CD and 25% in UC (P = 0.21). CD group had a higher SFRR than UC group (41% vs 20%) at 52 weeks, although the difference was not statistically significant. Similar clinical and endoscopic rates were observed in biologic-naive and -experienced patients. We reported no discontinuation due to adverse drug reactions, and only mild to moderate events. CONCLUSIONS: In our cohort the clinical response in the induction phase was similar to those of registered trials, despite surprising better results for CD. During the maintenance phase we observed an higher drop out than in the reported literatures. Of note, its good safety profile makes vedolizumab a reliable choice in patients with contraindications to anti-tumor necrosis factor agents.

A medical student-staffed outpatient oncology clinic: a 10-year Brazilian experience.

BACKGROUND: This is an update of a 10-years student-staffed oncology clinic. METHODS: Students are divided into 4 teams; each sees 1 to 2 outpatients weekly. RESULTS: By April 2006, 95 medical students participated, 89% for 2 or more years; 70% reported activity contributed to ability to read medical papers, and 59% improved their scientific writing. Of 39 students currently involved, 33 (84%) improved clinical skills in taking history, 27 (69%) in physical examination, and 34 (87%) in physician-patient relation. A total of 21 (56%) reported increased knowledge in general internal medicine. Although only 11% of former students pursued a specialty in Medical Oncology, 77% rated this clinic as the best extracurricular activity. CONCLUSIONS: Attendance of outpatient clinic in medical oncology can contribute significantly to the general medical education.

Multivitamins do not improve radiation therapy-related fatigue: results of a double-blind randomized crossover trial.

BACKGROUND: Fatigue is a common symptom in cancer patients receiving radiation therapy. PATIENTS AND METHODS: We conducted a double-blind randomized crossover trial of multivitamins versus placebo in patients with breast cancer undergoing radiation therapy to evaluate fatigue and quality of life. RESULTS: : We randomized 40 patients to either placebo or Centrum Silver. At the middle of the radiation treatments, patients were switched from placebo to multivitamins and vice versa. Patients answered the EORTC QLQ C-30 quality of life (QOL) and Chalder fatigue questionnaires at the beginning, middle, and end of radiation therapy. Both groups experienced decreases in general (P = 0.009; P = 0.001) and physical fatigue scores (P = 0.031; P = 0.029) at the end of the course of placebo compared with the assessment prior to this treatment. We also observed significant improvements in functional (P = 0.026) and symptoms (P = 0.016) score scales of the QOL questionnaire in the patients on placebo. No significant changes were elicited with the use of multivitamins. We also observed significantly lower rates of fatigue in the patients who had just finished a course of placebo as compared with patients finishing a course of multivitamins (0 vs. 25% P = 0.035). CONCLUSION: Multivitamins do not improve radiation-related fatigue in patients with breast cancer.

Prevalence of the burnout syndrome among Brazilian medical oncologists.

INTRODUCTION: Burnout syndrome which is prevalent among oncologists is characterized by three aspects: emotional exhaustion, depersonalization and low personal accomplishment. The purpose was to evaluate prevalence of the burnout syndrome among Brazilian medical oncologists and the variables that correlate with its presence. METHODS: A survey was conducted with members of the Brazilian Society of Medical Oncology (SBOC) who received three questionnaires (general, Maslach burnout questionnaire and an opinion survey) mailed to all 458 members. RESULTS: Response rate was of 22.3%. According to the criteria proposed by Grunfeld, which consider burnout present when at least one of the aspects is severely abnormal, prevalence of this syndrome was 68.6% (95% confidence interval, CI: 58.68% to 77.45%). By multivariate analysis having a hobby/physical activity, a religious affiliation, older age, living with a companion and rating vacation time as sufficient were correlated significantly and independently with burnout syndrome. CONCLUSIONS: The burnout syndrome is prevalent among Brazilian oncologists. Oncologists having sufficient personal and social resources to engage in a hobby, physical activity, have enough vacation time and religious activities are at lower risk of developing burnout.

Onde está o atraso? Avaliação do tempo necessário para o diagnóstico e tratamento do câncer de mama nos serviços de oncologia da Faculdade de Medicina do ABC / Where is the delay? Evaluation of the necessary time for the diagnosis and tratment of breast cancer at the oncology services from ABC`s medcial school

Foi estatisticamente significante a associação entre a realização do auto-exame e o menor intervalo de tempo entre o primeiro sintoma e o agendamento da consulta (p = 0,042). Não se encontraram outras relações estatisticamente significativas. O principal fator responsável pelo atraso no diagnóstico e tratamento do câncer de mama em nosso meio é a busca de atenção médica após a descoberta da anormalidade mamária, que é significativamente menor em pacientes que praticam o auto-exame. No Brasil, o câncer de mama é o mais prevalente, sendo diagnosticado freqüentemente em estádios avançados. É essencial identificar o tempo para o diagnóstico do câncer de mama desde a detecção do primeiro sintoma até o início do tratamento, assim como analisar outros fatores associados a eventuais atrasos. Realizou-se estudo transversal mediante a aplicação de questionários em pacientes portadoras de câncer de mama já diagnosticado, com perguntas de caráter demográfico e referentes aos intervalos entre o aparecimento do primeiro sintoma, avaliação médica, biópsia e tratamento. Foram entrevistadas 91 pacientes não consecutivas (média de idade: 53,3 anos), e 49,5% tinham escolaridade inferior ao ensino fundamental completo. O maior intervalo de tempo ocorreu entre a detecção do primeiro sintoma e a marcação da primeira consulta médica.

In Brazil, breast cancer is prevalent disease that is unfortunately often diagnosed in advanced stages. Identify the time intervals involved on the diagnosis of breast cancer since detection of the first abnormality until the beginning to treatment, as well as the determinant factors involved in these delays. Transversal survey of breast cancer patients already diagnosed with breast cancer. We employed two questionnaires aiming at describing their demographic characteristics as well as detailing each time interval from the first symptom to the medical evaluation, biopsy and treatment. We surveyed 91 non-consecutive patients (mean age: 53.3 years) and 49.5% have not completed primary school. The largest time interval was recorded from the first noted abnormality by the patient and scheduling the first medical appointment. We observed a statistically significant relation between doing periodic self breast exam and a smaller time interval from symptom notice to scheduling of her first evaluation (P = .042). We have found no other significant correlations. The largest delay in the time from the first symptom to treatment was related to the scheduling of the first medical appointment which is significantly smaller in patients who do periodic self breast examination.

Prevalence of the burnout syndrome among Brazilian medical oncologists

INTRODUCTION: Burnout syndrome which is prevalent among oncologists is characterized by three aspects: emotional exhaustion, depersonalization and low personal accomplishment. The purpose was to evaluate prevalence of the burnout syndrome among Brazilian medical oncologists and the variables that correlate with its presence. METHODS: A survey was conducted with members of the Brazilian Society of Medical Oncology (SBOC) who received three questionnaires (general, Maslach burnout questionnaire and an opinion survey) mailed to all 458 members. RESULTS: Response rate was of 22.3 percent. According to the criteria proposed by Grunfeld, which consider burnout present when at least one of the aspects is severely abnormal, prevalence of this syndrome was 68.6 percent (95 percent confidence interval, CI: 58.68 percent to 77.45 percent). By multivariate analysis having a hobby/physical activity, a religious affiliation, older age, living with a companion and rating vacation time as sufficient were correlated significantly and independently with burnout syndrome. CONCLUSIONS: The burnout syndrome is prevalent among Brazilian oncologists. Oncologists having sufficient personal and social resources to engage in a hobby, physical activity, have enough vacation time and religious activities are at lower risk of developing burnout.

INTRODUÇÃO: A Síndrome da Estafa Profissional (SEP) é considerada uma doença caracterizada por três componentes básicos: exaustão emocional (EE), despersonalização (DP) e reduzida realização pessoal (RP), sendo identificada em oncologistas. OBJETIVO: Analisar a prevalência da SEP entre oncologistas clínicos e possíveis fatores relacionados. MÉTODOS: Foram enviados três questionários (Questionário Geral, Questionário Maslach de Burnout e Questionário de Opinião) para 458 cancerologistas cadastrados na Sociedade Brasileira de Oncologia Clínica (SBOC). RESULTADOS: A taxa de resposta foi de 20 por cento. 43,3 por cento dos entrevistados demonstraram nível baixo de EE, 57,8 por cento apresentaram nível alto de DP e 55,5 por cento alta RP. Para avaliarmos a presença da SEP, utilizamos o critério de Ramirez, que considera as três dimensões em nível grave (8,9 por cento) e o de Grunfeld que considera pelo menos um dos três domínios em nível grave (68,9 por cento). Pelos critérios de Ramirez, houve correlação negativa com praticar exercícios/hobby (p=0,0007) e crer em uma religião (p=0,0445) com SEP. Já por Grunfeld, se correlacionou positivamente com morar com o companheiro (p=0,0054) e considerar o tempo de férias insuficiente (p=0,0037). Por ambos os critérios, foi constatada uma correlação positiva entre ter a síndrome e não optar por oncologia novamente se tivesse essa oportunidade. CONCLUSÃO: A SEP é muito prevalente entre os oncologistas clínicos. Porém, a maioria destes profissionais optaria novamente por essa especialidade. Prática de exercícios/hobby, tempo de férias suficiente e crer em uma religião surgiram como possíveis fatores para prevenir esta síndrome.

[Awareness of cancer diagnosis does not lead to depression in palliative care patients]. / O conhecimento do diagnóstico de câncer não leva à depressão em pacientes sob cuidados paliativos.

OBJECTIVE: Characterize the profile of patients under palliative care at this institution and evaluate the prevalence of depression in these patients. METHODS: Sixty two cancer patients under palliative care, who had answered three questionnaires: one regarding their demographic characteristics, another to evaluate their quality of life and the Beck's depression inventory were surveyed. RESULTS: Of these patients, 68% presented with some degree of depression. Most of them were aware of their diagnosis (87.1%), did not talk to their physicians on other subjects but their disease (81.18%), were satisfied with their treatment (93.33%) and with the support they received (95.70%). Pain, fatigue, weakness and sleep disturbances were the most frequently reported symptoms. There was a significant correlation between presence of depression and not knowing the diagnosis (p=0.008), being admitted to the hospital (p=0.0019) and not having ever received oncologic treatment. CONCLUSION: Patients under palliative care at this institution, despite being satisfied with the treatment, reported poor communication with their physicians and presented with a high rate of depression. Awareness of their diagnosis and having received prior oncologic treatment (p=0.07) correlated significantly and inversely with having depression.

O conhecimento do diagnóstico de câncer não leva à depressão em pacientes sob cuidados paliativos / Awareness of cancer diagnosis does not lead to depression in palliative care patients

OBJETIVOS: Traçar o perfil e identificar a prevalência de depressão nos pacientes sob cuidados paliativos no Serviço de Oncologia da Faculdade de Medicina do ABC. MÉTODOS: Entrevistamos 62 pacientes oncológicos em cuidados paliativos que responderam a três questionários: questionário geral contendo variáveis demográficas, questionário estruturado para pacientes oncológicos em cuidados terminais para avaliação de sua qualidade de vida e inventário de depressão de Beck. RESULTADOS: Observamos que 68 por cento dos pacientes tinham algum grau de depressão. A maioria dos pacientes sabia seu diagnóstico (87,1 por cento), estava satisfeito com o tratamento (93,33 por cento), sentia-se satisfeito com o apoio recebido (95,7 por cento) e referiu não conversar com seus médicos sobre outros assuntos além de sua saúde (81,18 por cento). Os sintomas mais freqüentes foram dor, cansaço, fraqueza e alterações do sono. Encontramos que o fato de não saber o diagnóstico (p=0,008), estar internado (p=0,0019) e não ter recebido tratamento oncológico (p=0,007) se correlacionam significativamente com níveis mais altos de depressão. CONCLUSÃO: Pacientes sob cuidados paliativos em nosso meio, apesar de geralmente satisfeitos com seu cuidado, relatam pobre comunicação com seu médico e apresentam uma alta taxa de depressão. Saber o seu diagnóstico e ter recebido tratamento oncológico se correlacionam inversamente com a presença de depressão.

OBJECTIVE: Characterize the profile of patients under palliative care at this institution and evaluate the prevalence of depression in these patients. METHODS: Sixty two cancer patients under palliative care, who had answered three questionnaires: one regarding their demographic characteristics, another to evaluate their quality of life and the Beck's depression inventory were surveyed. RESULTS: Of these patients, 68 percent presented with some degree of depression. Most of them were aware of their diagnosis (87.1 percent), did not talk to their physicians on other subjects but their disease (81.18 percent), were satisfied with their treatment (93.33 percent) and with the support they received (95.70 percent). Pain, fatigue, weakness and sleep disturbances were the most frequently reported symptoms. There was a significant correlation between presence of depression and not knowing the diagnosis (p=0.008), being admitted to the hospital (p=0.0019) and not having ever received oncologic treatment. CONCLUSION: Patients under palliative care at this institution, despite being satisfied with the treatment, reported poor communication with their physicians and presented with a high rate of depression. Awareness of their diagnosis and having received prior oncologic treatment (p=0.07) correlated significantly and inversely with having depression.

[Acceptance of chemotherapy by Brazilian women with breast cancer]. / Aceitação de quimioterapia por brasileiras com câncer de mama.

INTRODUCTION: Breast cancer has the second highest incidence and is the first cause of death by cancer among Brazilian women. Under the physician's perspective chemotherapy should be indicated according to the risk benefit ratio in each case. However, from the Brazilian breast cancer patient's perspective this risk benefit ratio requires further classification. OBJECTIVE: In patients with breast cancer who have already received chemotherapy evaluate the minimum benefit considered necessary for a renewed administration and learn which factors may influence this decision. METHODS: we surveyed 53 patients comprising general, clinical and cancer related variables, as well as issues related to the minimal expected benefit which would induce the patient to agree to undergo chemotherapy. RESULTS: 75% would accept to receive chemotherapy again even if it would not change their probability of relapse, 50% would accept chemotherapy again, even though it would not increase survival rates. Similarly, 81.54% would submit once more to chemotherapy even though it would not increase their probability of cure. Acceptance of a new chemotherapy treatment yielding minimal benefits correlated significantly with more age, with a lower educational level and with no previous administration of Adriamycin. CONCLUSION: Even with a minimal benefit, the majority of formerly treated breast cancer patients are willing to submit to another chemotherapy treatment.

Aceitação de quimioterapia por brasileiras com câncer de mama / Acceptance of chemotherapy by Brazilian women with breast cancer

INTRODUÇAO: O câncer de mama é o segundo tipo de câncer mais incidente e a primeira causa de morte por câncer entre as mulheres brasileiras. Na perspectiva do médico, a indicação da quimioterapia adjuvante como parte de seu tratamento deve se pautar pelos seus riscos e benefícios. Do ponto de vista da paciente, entretanto, em nosso meio, há poucos dados acerca de suas opiniões quanto à magnitude dos benefícios e riscos associados a este tratamento. OBJETIVOS: Avaliar o benefício mínimo necessário para que pacientes com câncer de mama que já tenham realizado quimioterapia aceitem-na novamente, caso hipoteticamente isso se fizesse necessário e conhecer fatores que, eventualmente, poderiam influenciar nessa decisão. MÉTODOS: Foram aplicados questionários a 52 pacientes sobre dados gerais e clínicos de cada paciente, além de perguntas a respeito do benefício mínimo necessário para a aceitação de uma eventual nova quimioterapia. RESULTADOS: 75 por cento fariam uma nova quimioterapia mesmo se ela não alterasse a chance de recidiva da doença em cinco anos; metade das pacientes a fariam mesmo que esta não aumentasse a sua sobrevida e 61,54 por cento se submeteriam novamente a um tratamento quimioterápico mesmo que este não aumentasse a sua chance de cura. A aceitação de uma nova quimioterapia que produzisse mínimos benefícios foi significativamente maior dentre pacientes mais idosas, com menor escolaridade e entre aquelas que não receberam quimioterapia prévia com adriamicina. CONCLUSAO: Mesmo por um benefício muito pequeno, a grande maioria das pacientes estudadas aceitaria ser submetida a uma nova quimioterapia, se indicada por seus médicos.